Member Info for Beamer21

I’m seen this algo at work on several companies recently - so easy on SETS to move the price in whatever direction it chooses

https://www.sharesmagazine.co.uk/news/shares/funding-circle-dips-despite-gaining-market-share#.YAVujMqWJuQ.twitter

My guess is that beleaguered Jupiter are selling which has caused a drag on the potential upside here - very peculiar trading activity with large premiums paid for volume

https://www.investegate.co.uk/funding-circle-hldgs--fch-/rns/h2-2020-trading-update/202101180700079372L/

As at 13 December 2020, we represented c.25% share of the number of CBILS loans approved since we began participating in the scheme. When CBILS ends we will operate our core lending product alongside the long term government guarantee programme previously announced by HM Treasury.

Tipped in the telegraph - Interims tomorrow

FDA approval gives a boost with Moderna expected imminently

Brexit causing general market malaise but from today’s update it’s clear RR have weathered the storm and are positioned well to benefit from green shoots

True spread is currently around 3.61/3.69

Absolute manipulation ahead of sunaks spending review

now

It’s still in auction Kiwi

It’s in auction

As reported in March 2020, Vectura has estimated that damages, accumulated interest and ongoing royalties could amount to approximately $200m in total. The precise amounts to be received are dependent on the future US sales of the infringing products as well as sales for historical periods yet to be reported by GSK.

Will Downie, Chief Executive Officer of Vectura, commented: "We are very pleased with the result of this appeal, which confirms the validity of our intellectual property and the decision to progress this litigation with GSK. Once we have further clarity regarding final settlement and potential timing of receipts, we will provide a further market update."

GlaxoSmithKline PLC has lost an appeal seeking to overturn an $89.7 million verdict a jury handed down after finding that the company's Ellipta line of inhalers infringed a patent belonging to rival drug company Vectura Ltd.

A unanimous three-judge panel of the U.S. Court of Appeals for the Federal Circuit ruled Thursday that there was no grounds to overturn the verdict or to order a new trial, rejecting GSK's arguments that a lower court should have granted it judgment of non-infringement and that a Vectura lawyer made improper statements in court.

Await official confirmation but am I correct in thinking a $200m windfall is coming as per the statement below?

GSK Litigation

Following a US Jury trial in May 2019, Vectura was awarded damages and estimated ongoing royalties amounting to approximately $200m, based upon the application of a 3% royalty rate to US sales of GSK infringing products for the period August 2016 to the expiration of Vectura's patent in mid-2021. Interest will also accrue on damages at the Treasury bill rate, compounded annually. No amounts have been recognised in the H1 2020 results in respect of these damages.

GSK has initiated an appeal in the US, with a hearing currently scheduled for 5th October 2020. Based on the present appeal briefing schedule, a decision is likely to be received before the end of Q1 2021.

Financial review

Following the Group's shift in business model to a contract development and manufacturing organisation (CDMO), the Board has reviewed the presentation of the Income statement to assess whether it continues to provide reliable and relevant information about the effects of transactions, other events or conditions on the financial performance of the Group.

Buy side currently Stacked for a move north

Received one last year 19th November so maybe around the same time, H2 was expected to be stronger in the last update

News of Virolens orders and in full production could move this exponentially

ETF flew 10.54% yesterday, currently down 27% YTD

NYC looking to legalise it in 2021 - Cuomo is a supporter

Up 3.7%

https://www.ft.com/content/c1ee03d4-f22e-4514-af46-2f8423a6842e